Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

Tapinarof Cream 1% is FDA Approved
May 24, 2022

Dermavant’s new topical treatment for plaque psoriasis in adults was approved by the FDA this morning.

FDA Grants Fast Track Designation to TMB-001
April 28, 2022

The designation is for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis lamellar ichthyosis (ARCI-LI).

FDA Accepts BLA Resubmission for DAXI Injections
April 22, 2022

Revance Therapeutics announces the FDA has accepted the resubmission for daxibotulinumtoxinA for injection of glabellar lines.

Enrollment in ARRECTOR Pivotal Phase 3 Trial Completed
April 21, 2022

Arcutis Biotherapeutics announced news of its topical roflumilast foam’s trial on safety and efficacy of treatment in scalp and body psoriasis.

On the Radar: Emerging Biologics, Topical Anti-Inflammatories, and Systemic Treatments for AD
April 10, 2022

Expert panelists discussed the pros, cons, and unknowns of the fast-growing roster of new AD treatments in a session at the 4th Annual Revolutionizing Atopic Dermatitis Conference held April 9 to 11, 2022 in Baltimore, Maryland.

Efficacy of Spesolimab for GPP Flare Treatment
April 01, 2022

A poster from the 2022 American Academy of Dermatology Annual Meeting presented subgroup analyses from the Effisayil 1 study that showed the efficacy of spesolimab was consistent across all prespecified patient populations, including those with or without IL-36RN mutations.

What's Happening in the Vitiligo Pipeline?
April 01, 2022

In this drug pipeline video, Pearl Grimes, MD, FAAD, and Seemal R. Desai, MD, FAAD discuss what's currently happening in the vitiligo pipeline including why current treatments are lacking, what's coming soon, and what it may cost.

Late Breaking Research: Congenital Ichthyosis
March 26, 2022

In this video interview, Christopher Bunick, MD, PhD dives into the topic of congenital ichthyosis describing his talk on the skin condition at the American Academy of Dermatology 2022 Annual Meeting.

FDA Places Partial Clinical Hold on Phase 1 Trial of Davoceticept Pembrolizumab in Advanced Malignancies
March 17, 2022

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

Phase 2 Difelikefalin Data for AD to be Presented at AAD 2022
March 11, 2022

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.